South Korean manufacturer's botulinum toxin sales power record first-half results, driven by international expansion.
Hugel reported record H1 2026 results, with botulinum toxin sales driving growth across global aesthetics and cosmetics divisions. The Seoul-based company's international footprint expansion—particularly in emerging markets where regulatory pathways are opening—has offset mature-market saturation and generic pressure.
Hugel's toxin portfolio includes BOTULAX and NEURONOX, both competing in price-sensitive geographies where AbbVie and Evolus have limited penetration. The record H1 reflects both volume growth and favorable FX, but also signals that toxin commoditization is advancing fastest in developed markets, pushing manufacturers to pursue emerging-market share and adjacent indications.
Hugel posted record H1 results, with botulinum toxin sales driving growth across international markets.
For U.S. practice owners, Hugel's momentum underscores the global nature of toxin supply chains and pricing pressure. If Hugel accelerates U.S. market entry or expands gray-market availability, domestic pricing could face renewed compression.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
